Meta-analysis Reveals the Prognostic Value of Circulating Tumour Cells Detected in the Peripheral Blood in Patients with Non-Metastatic Colorectal Cancer

• Published in: Scientific reports Vol. 7; no. 1; pp. 905 - 9
• Main Authors: Lu, Yan-jun, Wang, Peng, Peng, Jing, Wang, Xiong, Zhu, Yao-wu, Shen, Na
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 19.04.2017; Nature Publishing Group; Nature Portfolio
• Subjects: 45/77; 692/53/2422; 692/699/67/2324; 82/51; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - blood; Colorectal Neoplasms - pathology; Disease Progression; Humanities and Social Sciences; Humans; Medical prognosis; Meta-analysis; Metastases; Metastasis; multidisciplinary; Neoplastic Cells, Circulating - pathology; Peripheral blood; Prognosis; Regression Analysis; Science; Science (multidisciplinary); Survival Analysis; Tumors
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-017-01066-y

Detecting circulating tumour cells (CTCs) is considered as effective and minimally invasive technique to predict the prognosis of patients with metastatic colorectal cancer (CRC), but its clinical validity is still conflicting in patients without metastasis. We performed this meta-analysis to evaluate whether detection of CTCs in the peripheral blood can be used as a prognostic marker for patients with non-metastatic CRC. We performed a comprehensive search of the EMBASE, PubMed, and Web of Science databases (up to September 2016). Meta-analyses were conducted using a random-effects model with the hazard ratio (HR) and 95% confidence interval (95% CI) as the effect measures. Twenty studies including 3,687 patients were eligible for inclusion. Overall analyses demonstrated that the presence of CTCs was significantly associated with aggressive disease progression (HR = 2.57, 95% CI = 1.64–4.02, P heterogeneity  < 0.001, I 2  = 81.0%) and reduced disease survival (HR = 2.41, 95% CI = 1.66–3.51, P heterogeneity  = 0.002, I 2  = 59.7%). Subgroup analyses further supported the prognostic effect of CTCs based on different subsets, including sampling time, detection method and cancer type. Our findings suggest that detection of CTCs in the peripheral blood has the clinical utility to indicate poor prognosis in patients with non-metastatic CRC.